Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies ...

During the pandemic, money flooded into drugmakers’ shares but recently more investors are shifting into Big Tech ...

FDLO's sector-neutral approach and selective stock picking drive strong profitability and historical earnings growth. Read why FDLO ETF is a Buy.

Eli Lilly & Co. closed 20.16% below its 52-week high of $972.53, which the company achieved on August 22nd.

Eli Lilly and Company (NYSE:LLY) is one of the stocks that Jim Cramer shed light on. While Cramer still backed the company, he did express uncertainty about its future as he stated: “What I’m thinking ...

Indianapolis, Indiana-based Eli Lilly and Company (LLY) is a pharmaceutical company that discovers, develops, and markets ...

Eli Lilly closed at $1.87, ranked 34th in trading volume on July 22, 2025. BMO Capital remains bullish, reiterating a buy ...

The French biotech is developing a new drug approach in a disease market that’s projected to grow to $30 billion by 2030.

Global healthcare stocks have not been this cheap in decades and fund inflows into the sector are picking up, yet the shares remain in the doldrums, highlighting uncertainty over drug pricing policies ...

The atopic dermatitis market, valued at USD 9.33 billion in 2024, is projected to grow at a CAGR of 15.10%, reaching USD 38.07 billion by 2034. Key d ...

Equity Investment Corp recently purchased 574 shares of Meta Platforms, valued at roughly $331,000, signaling strong ...